Assessment of the biochemical markers of inflammation (plasma hs-CRP and IL-6 ) and thrombosis (plasma fibrinogen, plasminogen activator inhibitor) in Omani patients with myocardial and recurrent myocardial infarction

The risk of acute coronary syndrome (ACS) including myocardial infarction (MI) with its associated risk factors and complications is high in the Arabian Gulf countries as shown by the results of INTERHEART middle East, Gulf RACE and Gulf COAST studies. Patients who survive the first acute MI are considered at high risk for recurrent MI and mortality which can be attributed mainly to uncontrolled traditional risk factors like diabetes, hypertension, smoking, hypercholesterolemia and obesity. Moreover, recurrent MI can also be caused by emerging risk factors like lipoprotein (a), thrombosis, inflammation, coronary artery disease polygenetic risk score (CAD PRS) and others. The frequency of recurrent MI varies between country to country. In the Arabian Gulf region and Oman, we have limited data on impact of the emerging biochemical markers for inflammation and thrombosis on single and subsequent recurrent MI. Therefore, this study aims to assess the impact of the emerging biochemical markers for inflammation and thrombosis in the risk of myocardial and recurrent myocardial infarction in Omani patients.